# **UCSF**

# **UC San Francisco Previously Published Works**

# Title

Nuevo Amanecer-II: Results of a randomized controlled trial of a community-based participatory, peer-delivered stress management intervention for rural Latina breast cancer survivors

# **Permalink**

https://escholarship.org/uc/item/2030s6nw

# **Journal**

Psycho-Oncology, 29(11)

# **ISSN**

1057-9249

# **Authors**

Nápoles, Anna María Santoyo-Olsson, Jasmine Stewart, Anita L et al.

# **Publication Date**

2020-11-01

#### DOI

10.1002/pon.5481

# **Copyright Information**

This work is made available under the terms of a Creative Commons Attribution License, available at <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a>

Peer reviewed

#### **PAPER**

WILEY

# Nuevo Amanecer-II: Results of a randomized controlled trial of a community-based participatory, peer-delivered stress management intervention for rural Latina breast cancer survivors

Anna María Nápoles<sup>1</sup> | Jasmine Santoyo-Olsson<sup>2</sup> | Anita L. Stewart<sup>3,4</sup> Carmen Ortiz<sup>5</sup> | Cathy Samayoa<sup>6</sup> | Alma Torres-Nguyen<sup>7</sup> | Helen Palomino<sup>8</sup> | LaVerne Coleman<sup>9</sup> | Aday Urias<sup>8</sup> | Nayeli Gonzalez<sup>8</sup> | Silvia Araceli Cervantes<sup>7</sup> | Vicken Y. Totten<sup>7</sup>

#### Correspondence

Anna María Nápoles, PhD, MPH, Division of Intramural Research, National Institute on Minority Health and Health Disparities, National Institutes of Health,, 9000 Rockville Pike,, Building 3, Floor 5, Room E08, Bethesda, MD 20892 USA.

Email: anna.napoles@nih.gov

#### **Abstract**

Objective: We report results of a community-based multisite, randomized controlled trial of Nuevo Amanecer (NA-II), a 10-week stress management program for rural, low literacy Latina breast cancer survivors.

Methods: Trained peers delivered NA-II to Spanish-speaking Latinas with nonmetastatic breast cancer in three rural communities. Women were randomized to receive the program immediately or wait 6 months. Assessments were conducted at baseline, 3 months, and 6 months. Primary outcomes were breast cancer-specific quality of life domains; secondary outcomes included general distress symptoms and stress management skills. Intention-to-treat analyses using repeated-measures linear regression models estimated changes in slope between groups.

Results: Of 153 participants (76 randomized to intervention, 77 to control group), 92% were retained at 6 months. Mean age was 54.8 years (SD = 10.5); 80% had less than high school education. There were no statistically significant treatment x time effects on quality of life. Compared to women in the control group, intervention group women reported greater improvements in anxiety at 6 months (-0.20 vs -0.02, P = .049; range 0-4) as well as three stress management skills: relaxation at 3 months ( $\pm 0.98$  vs  $\pm 0.07$ , P < 0.001; range 0-4) and 6 months ( $\pm 0.82$  vs  $\pm 0.04$ , P < .001), awareness of tension at 3 months (+0.31 vs -0.19, P < .01; range 0-4) and 6 months ( $\pm 0.29$  vs -0.11, P < .05), and coping confidence at 3 months ( $\pm 0.12$  vs -0.23, P < .01; range 0-4).

Conclusions: Stress management programs delivered by trained peers in rural community settings can reduce anxiety and improve stress management skills among Latina breast cancer survivors.

Trial registration: http://www.ClinicalTrials.gov identifier NCT02931552.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Published 2020. This article is a U.S. Government work and is in the public domain in the USA.

<sup>&</sup>lt;sup>1</sup>Division of Intramural Research, National Institute on Minority Health and Health Disparities, National Institutes of Health, Bethesda, Maryland

<sup>&</sup>lt;sup>2</sup>Division of General Internal Medicine, Department of Medicine, University of California San Francisco (UCSF), San Francisco, California

<sup>&</sup>lt;sup>3</sup>Center for Aging in Diverse Communities, University of California San Francisco, San Francisco, California

<sup>&</sup>lt;sup>4</sup>Institute for Health & Aging, University of California San Francisco, San Francisco,

<sup>&</sup>lt;sup>5</sup>Círculo de Vida Cancer Support and Resource Center, San Francisco, California

<sup>&</sup>lt;sup>6</sup>Health Equity Research Lab, Department of Biology, San Francisco State University, San Francisco, California

<sup>&</sup>lt;sup>7</sup>Kaweah Delta Health Care District, Visalia, California

<sup>&</sup>lt;sup>8</sup>Cancer Resource Center of the Desert, El Centro, California

<sup>&</sup>lt;sup>9</sup>WomenCARE/Entre Nosotras, Family Service Agency of the Central Coast, Park, California

#### **Funding information**

California Breast Cancer Research Grants
Program Office of the University of California,
Grant/Award Number: 21OB-0135; Division
of Intramural Research, National Institute on
Minority Health and Health Disparities;
National Institute on Aging, Grant/Award
Number: P30 AG15272; National Institute on
Minority Health and Health Disparities;
University of California

#### **KEYWORDS**

cancer, breast cancer survivors, community-based participatory research, Latino/Hispanic, psychological distress, psycho-oncology, quality of life, randomized controlled trial, rural communities, stress management

#### 1 | BACKGROUND

Rural Latina breast cancer survivors are particularly vulnerable, experiencing poverty, legal status issues, language barriers, and limited health and breast cancer care, transportation, education, and childcare. Additionally, Latina breast cancer survivors in the U.S. who live near the U.S.-Mexico border have unique problems due to bi-national health care seeking, poor cancer care coordination, regional shortages of cancer specialists, and financial hardship. Rural Latino cancer survivors reported language discordance with clinicians, unsatisfactory communication via medical interpreters, and lack of clarity of clinician communication. Consequently, they are at elevated risk of chronic stress and poor health-related quality of life.

Cognitive-behavioral stress management interventions have been demonstrated in randomized controlled trials (RCTs) to: increase relaxation and positive affect; reduce anxiety, depressive symptoms, and serum cortisol; and improve quality of life among breast cancer survivors. Furthermore, such interventions may improve survival and reduce risk of recurrence among women with non-metastatic breast cancer. 8,9

Latina breast cancer survivors report higher rates of anxiety, depression, fear of recurrence, fatigue, pain, and worse health-related quality of life than their White counterparts. At least five randomized controlled trials (RCTs) have tested psychosocial interventions focused on stress reduction among Latinas. Alored However, RCTs testing psychosocial interventions among *rural* Latina breast cancer survivors are needed. One small study (N = 14) tested a cognitive-behavioral stress management program in patients with varied types of cancer in rural New England settings.

Our original *Nuevo Amanecer* (*NA*) program was designed for newly diagnosed Latina breast cancer survivors in urban settings and successfully improved several quality of life domains and decreased breast cancer concerns and depressive and bodily symptoms. <sup>18</sup> We adapted *NA* for Latina breast cancer survivors living in rural settings and expanded the content to include self-care into survivorship to create *NA-II*. In this paper, we report the results of a community-based multisite, RCT of *NA-II* in settings serving rural Latinas with breast cancer.

#### 2 | METHODS

We provide a brief description of the NA-II program and study. Detailed descriptions of study settings, design, recruitment, adaptations, and program content are described elsewhere.<sup>19</sup>

# 2.1 | Settings

The study was conducted in three California sites serving Spanish-speaking Latina breast cancer survivors in rural areas that rely on agribusiness. Two were community-based organizations (CBOs) and one was a community hospital. The sites/community partners were Cancer Resource Center of the Desert (CRCD) (Imperial Valley), WomenCARE/Entre Nosotras (Watsonville/Salinas), and Kaweah Delta Health Care District (KDHCD)(Tulare County in the Central Valley). CRCD is the only non-profit organization in the Imperial Valley providing Spanish-language comprehensive cancer support and patient navigation services. WomenCARE is a cancer support program of the Family Service Agency of the Central Coast (a mental health services provider) and Entre Nosotras is the Spanish-language arm of WomenCARE. KDHCD is the only Visalia hospital offering comprehensive health care services, including community health workers who provide health education.

Community-based participatory research approaches were employed from study conceptualization to dissemination of results. Numerous individuals from each community setting were involved including field staff who were employees of the partner sites (project director, at least two recruiters, and at least two interventionists called *compañeras* at each site), clinicians, survivors, and organizational leaders. Ongoing participation of community members occurred through community consultations, weekly calls and monthly video-conferencing or in-person meetings with field staff, and review and pretesting of materials by community members. Trained community field staff implemented the study. A lead CBO and partner in the first RCT, *Circulo de Vida* Cancer Support and Resource Center (CDV), provided clinical supervision of field staff and assisted with training and implementation. CDV is a San Francisco Bay Area Spanish language cancer support services provider.

#### 2.2 | Study design

This was a 6-month RCT to assess the effectiveness of NA-II in improving breast cancer-specific quality of life (primary outcomes) at 3 and 6 months. <sup>19</sup> Secondary outcomes included four general distress symptoms, and attainment of four stress-management skills. We compared the 10-week NA-II intervention group to a wait-list control group. The University of California San Francisco Institutional Review Board (IRB) (protocol #16-18 737) and the KDHCDIRB (protocol #

20160434006) approved the study. UCSF was the IRB of record for the other two sites. Written informed consent was obtained. The study conforms to the U.S. Federal Policy for the Protection of Human Subjects and is registered at http://www.ClinicalTrials.gov (NCT02931552).

# 2.3 | Participants

Inclusion criteria, which were broad because this was an effectiveness trial, consisted of: (1) Spanish-speaking Latina (self-identified ethnicity); (2) diagnosis of Stage 0 to IIIC primary breast cancer; and (3) residing in the selected rural California communities (Imperial, Tulare, or Santa Cruz/Monterey counties) served by our community partners. Exclusion criteria were terminal illness, metastatic breast cancer diagnosis, or plans to move out of the area in six months.

# 2.4 | Recruitment

Eligibility screening and recruitment were conducted with a bilingual script by trained bilingual Latinas employed by the community-based partners. A project director at each site supervised recruiters. For the two CBO sites, recruiters identified potentially eligible women through intake records or outreach and education activities. KDHCD identified potentially eligible women through electronic health records and then mailed them an initial contact letter on their stationery, a study information sheet, and a prepaid refusal postcard to return to KDHCD. If no refusal postcard was received within two weeks, the site recruiter initiated telephone contact with the potential participant. Recruiters verified eligibility through medical or intake records.

# 2.5 | Nuevo Amanecer-II intervention

The NA-II program was adapted from NA to expand its generalizability for rural, low literacy Spanish-speaking Latina breast cancer survivors throughout survivorship. Adaptation processes for this trial are described in detail elsewhere. Social cognitive theory was the conceptual framework used for NA and NA-II. Adaptations for NA-II were based on new formative research with survivors, advocates, patient navigators, medical social workers, and iterative consultations with community representatives from the three rural areas. Results led to expansion of the program from 8 to 10 sessions to accommodate more practice of skills and healthy lifestyles content, greater use of audio-visuals, further simplification, and creation of a handout for family members providing information on the program.

The NA-II program included ten weekly modules which covered managing the impact of cancer, learning about breast cancer and survivorship, finding cancer information, getting support, identifying helpful and unhelpful thoughts, managing thoughts and mood, stress management techniques, managing activities that affect mood, healthy lifestyles, and goal-setting. The program emphasized

cognitive-behavioral coping skills training, coaching, and modeling to actively manage stress and emotions. Core components consist of stress management skills training (eg, deep breathing, guided imagery), cognitive reframing (turning unhelpful thoughts into helpful thoughts), effective communication (with clinicians, family, friends), setting goals, and self-regulation to achieve goals. Women were provided with general information on breast cancer survivorship (potential symptoms and side effects, survivorship care planning) and healthy lifestyles (nutrition and physical activity).

Potential *compañeras* (interventionists) who were Spanish-speaking breast cancer survivors and at least three years post-diagnosis with no active recurrence were identified by the community sites. The community Co-PI, a clinical psychologist at CDV, interviewed candidates using a structured protocol, selecting women who demonstrated excellent interpersonal communication skills, compassion, cultural awareness, and having processed their personal breast cancer experience.

Compañeras participated in a 3-day training (three eight-hour consecutive days) conducted in Spanish by the PI, Co-PI, and the Co-PI's clinical director. Interactive didactic sessions covered psychosocial reactions to breast cancer among Latinas, the theoretical basis of the program, and hands-on review of the modules with extensive demonstration and role modeling of cognitive-behavioral stress management skills. Compañeras were trained to model skills for participants.<sup>20</sup>

Compañeras and participants were provided with a step-by-step Spanish-language manual covering 10-weekly sessions. Each week at participants' homes, one 90-minute module was presented in-person using visuals and hands-on exercises to teach and reinforce concepts and skills.

# 2.6 | Assessments

Baseline, three-month, and six-month assessments corresponded with our aims of evaluating the 10-week intervention soon after completion (three months) and retention of benefits after program termination (six months). Trained, community-based recruiters conducted inperson 60-minute baseline assessments (in Spanish) in the participant's home or community partner office. Three- and six-month assessments (30-minute telephone surveys) were conducted by an experienced, bilingual research associate blinded to participants' group assignment. Study data were managed using REDCap.<sup>22</sup> Participants received \$90 for three surveys.

# 2.6.1 | Measures

Primary outcomes were breast cancer-specific quality of life measures. Secondary outcomes consisted of two types of measures: general distress symptoms and stress management skills. We describe the psychometric properties and descriptive statistics of measures in this sample (Table 1).

Breast cancer-specific quality of life was assessed using the Functional Assessment of Cancer Therapy - Breast (FACT-B),  $^{23}$  in Spanish.  $^{24}$  The FACT-B comprises five subscales on four dimensions of well-being (physical, social/family, emotional, functional) and one assessing concerns about breast cancer, and a summary index (FACT-B total score). Women were asked the extent to which statements applied to them during the prior 7 days with five response options ranging from 0 = not at all to 4 = very much. We used scales as modified in the original NA study based on results of psychometric analyses.  $^{18}$  We re-labeled the FACT-B functional well-being scale as "enjoyment of life" because items pertain to this more general aspect of well-being (eg, enjoy life, enjoy doing things, accepted illness).

FACT-B scales were scored by summing item responses after reversing some items, with higher scores indicating better quality of life. Possible score ranges are: physical well-being, 0 to 24; social/family well-being, 0 to 20; emotional well-being, 0 to 20; enjoyment of life, 0 to 16; and breast cancer concerns, 0 to 28. The total FACT-B score (overall quality of life) was the sum of the five subscales (range 0-108). Item-scale correlations ranged from 0.35 to 0.77 and Cronbach alphas were  $\geq$  0.74 for all scales, except for breast cancer concerns, which had item-scale correlations of 0.14 to 0.60 and Cronbach alpha = 0.62 (Table 1). We retained the breast cancer concerns scale since it is a part

of the FACT-B, a widely validated measure of breast cancer-specific quality of life.

Secondary outcomes of general distress symptoms were assessed with four measures: *depressive symptoms*, *perceived stress*, *anxiety*, and *somatization*. *Depressive symptoms* were assessed with thePHQ-8.<sup>25</sup> Respondents reported the frequency with which they were bothered by the symptoms over the last 2 weeks on a 4-point scale (0 = not at all, 1 = several days, 2 = more than half the days, and 3 = nearly every day). The score is calculated as the sum of the 8 items; scores range from 0 to 24; higher scores indicate more depressive symptoms. Itemscale correlations ranged from 0.49 to 0.62 and Cronbach alpha was 0.83.

Perceived stress was assessed using the 10-item Perceived Stress Scale (PSS Spanish version from the HCHS/SOL Sociocultural Ancillary Study). <sup>26,27</sup> Scores range from 0 to 40; higher scores indicate more stress. Item-scale correlations ranged from 0.38 to 0.73 and Cronbach alpha was 0.85.

Anxiety and somatization were assessed with two scales from the Brief Symptom Inventory (BSI).<sup>28</sup> Women were asked how much each symptom distressed or bothered them during the past 2 weeks with response options ranging from 0 = not at all to 4 = extremely. Scores are calculated as the mean of non-missing items (possible range 0-4); higher scores indicate more anxiety or somatization. In our sample,

TABLE 1 Nuevo Amanecer-II measures: descriptive statistics, internal-consistency reliability, and item-scale correlations (N = 153)

| Measure (variable)                              | Direction of Score  | # of<br>Items | Range of Item-scale<br>Correlations | Alpha | Possible<br>Range | Observed<br>Range | Mean Scale<br>Score (SD) |
|---|---------------------|---------------|-------------------------------------|-------|-------------------|-------------------|--------------------------|
| Breast Cancer-Specific Quality o                | f Life <sup>a</sup> |               |                                     |       |                   |                   |                          |
| Physical well-being                             | ↑ = better          | 6             | .4877                               | .84   | 0-24              | 2-24              | 17.4 (5.3)               |
| Social/family well-being                        | ↑ = better          | 5             | .4864                               | .79   | 0-20              | 0-20              | 13.6 (4.1)               |
| Emotional well-being                            | ↑ = better          | 5             | .3562                               | .74   | 0-20              | 2-20              | 14.4 (4.3)               |
| Enjoyment of life (Functional well-being)       | ↑ = better          | 4             | .3862                               | .75   | 0-16              | 4-16              | 11.0 (2.9)               |
| Breast cancer concerns                          | ↑ = better          | 7             | .1460                               | .62   | 0-28              | 8-28              | 17.4 (4.7)               |
| Overall quality of life<br>(FACT-B total score) | ↑ = better          | 27            | NA                                  | NA    | 0-108             | 33-108            | 73.7 (15.1)              |
| General Distress Symptoms                       |                     |               |                                     |       |                   |                   |                          |
| Depressive symptoms <sup>b</sup>                | ↑ = worse           | 8             | .4962                               | .83   | 0-24              | 0-24              | 6.7 (5.3)                |
| Perceived stress <sup>c</sup>                   | ↑ = worse           | 10            | .3873                               | .85   | 0-40              | 0-35              | 15.7 (7.3)               |
| Anxiety <sup>d</sup>                            | ↑ = worse           | 6             | .6275                               | .88   | 0-4               | 0-3.8             | 0.70 (0.76)              |
| Somatization <sup>d</sup>                       | ↑ = worse           | 6             | .3563                               | .70   | 0-4               | 0-3.6             | 0.70 (0.64)              |
| Stress Management Skills <sup>e</sup>           |                     |               |                                     |       |                   |                   |                          |
| Relaxation                                      | ↑ = better          | 2             | .49                                 | .66   | 0-4               | 0-4               | 2.0 (1.1)                |
| Awareness of tension                            | ↑ = better          | 3             | .5863                               | .76   | 0-4               | 0-4               | 2.4 (0.97)               |
| Assertiveness                                   | ↑ = better          | 3             | .6981                               | .87   | 0-4               | 0-4               | 2.6 (1.1)                |
| Coping confidence                               | ↑ = better          | 5             | .7383                               | .91   | 0-4               | 0-4               | 2.5 (0.91)               |

<sup>&</sup>lt;sup>a</sup>Breast cancer-specific quality of life scales = FACT-B scales.<sup>23</sup>

<sup>&</sup>lt;sup>b</sup>Depressive symptoms = PHQ-8.<sup>25</sup>

<sup>&</sup>lt;sup>c</sup>Perceived stress = Perceived Stress Scale.<sup>26</sup>

<sup>&</sup>lt;sup>d</sup>Anxiety and somatization = Brief Symptom Inventory scales.<sup>28</sup>

<sup>&</sup>lt;sup>e</sup>Stress management scales = Measure of Current Status Part A (MOCS-A).<sup>29</sup>

item-scale correlations were: *anxiety*, 0.62 to 0.75; *somatization*, 0.35 to 0.63. Cronbach alphas were: *anxiety*, 0.88; *somatization*, 0.70.

Stress management skills were assessed with the Measure of Current Status Part A (MOCS-A).  $^{29}$ The MOCS-A comprises four subscales: *relaxation, awareness of tension, assertiveness*, and *coping confidence*. These skill areas were addressed in the intervention. Women are asked the extent to which they can do each technique when under stress (response choices: 0 = I cannot do this at all, 1 = I can do this just a little bit, 2 = I can do this fairly well, 3 = I can do this very well, and 4 = I can do this extremely well). We used a Spanish translation from a study of Spanish-speaking prostate cancer survivors.  $^{30,31}$  Non-missing items are averaged with scores ranging from 0 to 4; higher scores indicate greater confidence in skills.

The 2-item *relaxation* scale assessed women's ability to use relaxation techniques (muscle relaxation, mental imagery) to reduce tension. The 3-item *awareness of tension* scale measures their ability to recognize bodily tension, stressful situations, and when they are becoming tense. The 3-item *assertiveness* scale measures the extent to which women are able to ask for help/support when needed and can clearly express their needs. The 5-item *coping confidence* scale measures their ability to re-examine their thoughts to gain a new perspective, decide how to cope with problems, come up with emotionally balanced thoughts, and choose the best coping responses. Item-scale correlations were: *relaxation*, 0.49; *awareness of tension*, 0.58 to 0.63; *assertiveness*, 0.69 to 0.81; *coping confidence*, 0.73 to


0.83. Cronbach alphas were: relaxation, 0.66; awareness of tension, 0.76; assertiveness, 0.87; coping confidence, 0.91.

Descriptive characteristics included age, language acculturation, <sup>32</sup> education, health insurance, employment status, financial hardship, ethnicity, national origin, U.S. or foreign-born, marital status, health care utilization, and presence of other chronic medical conditions. We assessed self-rated health using the standard item (In general, would you say your health is...poor, fair, good, very good, excellent) and a new parallel item focusing on mental health (In general, would you say your mental health is...), with the same responses. Breast cancer characteristics verified through medical records review included cancer type, stage at diagnosis, type of surgery, and type of treatment.

# 2.6.2 | Participant adherence and fidelity to intervention

To assess participant adherence, *compañeras* completed a structured program tracking form after each session that included the session date, location, and duration. Program adherence was defined as having completed at least 7 of 10 sessions.

For each *compañera*, at least one intervention session was selected based on convenience, for direct observation for fidelity assessment by the Co-PI. Of the 7 *compañeras*, 2 were observed twice. Long travel distances (up to 10 hours) and difficulty



**FIGURE 1** Flow of participants from screening to completion of follow-up assessment, *Nuevo Amanecer-II* study, California, September 2016 to March 2018

**TABLE 2** Baseline characteristics of Spanish-speaking rural Latina breast cancer survivors participating in the *Nuevo Amanecer-II* study, California, September 2016 to March 2018

| Characteristics  | Intervention<br>Group (n = 76) | Control<br>Group (n = 77) | P-values | Total Samp<br>(n = 153) |
|--|--------------------------------|---------------------------|----------|-------------------------|
| Age in years (mean, SD)<br>(range 28–88)   | 55.7 (10.4)                    | 53.8 (10.5)               | 0.313    | 54.8 (10.5)             |
| Education (n, %)   |                                |                           | 0.022    |                         |
| <sixth grade<="" td=""><td>38 (51)</td><td>22 (29)</td><td></td><td>60 (39)</td></sixth>               | 38 (51)                        | 22 (29)                   |          | 60 (39)                 |
| sixth grade to <high school<="" td=""><td>25 (33)</td><td>38 (49)</td><td></td><td>63 (41)</td></high> | 25 (33)                        | 38 (49)                   |          | 63 (41)                 |
| High school graduate or more   | 12 (16)                        | 17 (22)                   |          | 29 (19)                 |
| Health insurance (n, %)  |                                |                           | 0.324    |                         |
| Any private  | 14 (18)                        | 22 (29)                   |          | 36 (24)                 |
| Public insurance only  | 60 (79)                        | 54 (70)                   |          | 114 (75)                |
| None   | 1 (1)                          | 0 (0)                     |          | 1 (1)                   |
| Do not know  | 1 (1)                          | 1 (1)                     |          | 2 (1)                   |
| Employed full or part time (% yes)   | 14 (18)                        | 14 (18)                   | 0.970    | 28 (18)                 |
| Any financial hardship in past year (% yes)  | 38 (50)                        | 36 (47)                   | 0.688    | 74 (48)                 |
| Ethnicity (n, %)   |                                |                           | 0.135    |                         |
| Mexican  | 75 (99)                        | 74 (96)                   |          | 149 (97)                |
| Central America  | 1 (1)                          | 0 (0)                     |          | 1 (1)                   |
| Other  | 0 (0)                          | 3 (4)                     |          | 3 (2)                   |
| Limited English proficiency  | 64 (85)                        | 60 (78)                   | 0.239    | 124 (82)                |
| Married or living with partner (% yes)   | 49 (64)                        | 52 (68)                   | 0.690    | 101 (66)                |
| Poor or fair self-rated health (n, %)  | 41 (54)                        | 29 (38)                   | 0.043    | 70 (46)                 |
| Poor or fair self-rated mental health (n, %)   | 28 (38)                        | 26 (34)                   | 0.602    | 54 (36)                 |
| Breast Cancer Characteristics (n, %)   |                                |                           |          |                         |
| Type of breast cancer  |                                |                           | 0.721    |                         |
| DCIS   | 6 (8)                          | 9 (12)                    |          | 15 (10)                 |
| Invasive   | 59 (78)                        | 58 (75)                   |          | 117 (76)                |
| Inflammatory   | 7 (9)                          | 8 (10)                    |          | 15 (10)                 |
| Missing  | 4 (5)                          | 2 (3)                     |          | 6 (4)                   |
| Stage at Diagnosis   |                                |                           | 0.802    |                         |
| 0  | 5 (7)                          | 3 (4)                     |          | 8 (5)                   |
| 1  | 24 (32)                        | 21 (27)                   |          | 45 (29)                 |
| 2  | 27 (36)                        | 28 (36)                   |          | 55 (36)                 |
| 3  | 13 (17)                        | 14 (18)                   |          | 27 (18)                 |
| Missing  | 7 (9)                          | 11 (14)                   |          | 18 (12)                 |
| Surgical Treatment   |                                |                           | 0.519    |                         |
| Breast conserving  | 39 (51)                        | 37 (48)                   |          | 76 (48)                 |
| Mastectomy   | 34 (45)                        | 38 (49)                   |          | 72 (47)                 |
| No surgical treatment  | O (O)                          | 1 (1)                     |          | 1 (1)                   |
| Missing  | 3 (4)                          | 1 (1)                     |          | 4 (3)                   |
| Adjuvant Treatment   |                                |                           | 0.623    |                         |
| Radiotherapy and chemotherapy  | 48 (63)                        | 43 (56)                   |          | 91 (59)                 |
| Radiotherapy only  | 12 (16)                        | 16 (21)                   |          | 28 (18                  |
| Chemotherapy only  | 12 (16)                        | 10 (13)                   |          | 22 (14)                 |
|  |                                |                           |          |                         |
| No adjuvant treatment  | 3 (4)                          | 7 (9)                     |          | 10 (7)                  |

(Continues)

TABLE 2 (Continued)

| Characteristics  | Intervention<br>Group (n = 76) | Control<br>Group (n = 77) | P-values | Total Sample<br>(n = 153) |
|--|--------------------------------|---------------------------|----------|---------------------------|
| Years since most recent diagnosis (mean, SD)                   | 2.54 (3.6)                     | 2.51 (2.8)                | 0.950    | 2.5 (3.2)                 |
| Breast Cancer-Specific Quality of Life <sup>a</sup> (mean, SD) |                                |                           |          |                           |
| Physical well-being (scale 0-24)                               | 17.53 (5.16)                   | 17.21 (5.51)              | 0.706    | 17.4 (5.3)                |
| Social/family well-being (scale 0-20)                          | 13.11 (4.01)                   | 14.12 (4.10)              | 0.128    | 13.6 (4.1)                |
| Emotional well-being (scale 0–20)                              | 14.13 (4.36)                   | 14.64 (4.30)              | 0.472    | 14.4 (4.3)                |
| Enjoyment of life (functional well-being, scale 0–16)          | 10.86 (2.81)                   | 11.10 (2.96)              | 0.608    | 11.0 (2.9)                |
| Breast cancer concerns (scale 0-28)                            | 17.20 (4.69)                   | 17.50 (4.82)              | 0.692    | 17.4 (4.7)                |
| Overall quality of life (scale 0-108)                          | 72.90 (14.46)                  | 74.55 (15.71)             | 0.501    | 73.7 (15.1)               |
| General Distress Symptoms (mean, SD)                           |                                |                           |          |                           |
| Depressive symptoms (scale 0-24) <sup>b</sup>                  | 6.79 (5.06)                    | 6.65 (5.48)               | 0.870    | 6.7 (5.3)                 |
| Perceived stress (scale 0-40) <sup>c</sup>                     | 15.51 (7.63)                   | 15.95 (7.08)              | 0.715    | 15.7 (7.3)                |
| Anxiety (scale 0–4) <sup>d</sup>                               | 0.72 (0.73)                    | 0.68 (0.80)               | 0.722    | 0.70 (0.76)               |
| Somatization (scale 0-4) <sup>d</sup>                          | 0.67 (0.60)                    | 0.73 (0.67)               | 0.538    | 0.70 (0.64)               |
| Stress Management Skills <sup>e</sup> (mean, SD)               |                                |                           |          |                           |
| Relaxation (scale 0-4)   | 1.78 (1.13)                    | 2.13 (1.11)               | 0.053    | 2.0 (1.1)                 |
| Awareness of tension (scale 0-4)                               | 2.32 (0.88)                    | 2.49 (1.05)               | 0.283    | 2.4 (0.97)                |
| Assertiveness (scale 0-4)                                      | 2.59 (1.11)                    | 2.49 (1.22)               | 0.579    | 2.6 (1.1)                 |
| Coping confidence (scale 0-4)                                  | 2.45 (0.80)                    | 2.53 (1.01)               | 0.607    | 2.5 (0.91)                |

<sup>&</sup>lt;sup>a</sup>Breast cancer-specific quality of life scales = FACT-B scales.<sup>23</sup>

coordinating participant, *compañera* and Co-PI schedules prevented observation of more visits. Using structured rating scales, the Co-PI rated interventionists' compliance with six dimensions on a scale from 1 = not at all to 4 = constantly: extent to which they followed the manual content for that session; explained concepts in easy-to-understand language; checked with participant to ensure comprehension; used caring/supportive communication; modeled skills for participants; and provided feedback to participants on skills. Sessions were audiotaped, and reviewed and rated also by two research associates, using the same rating scale. Scores on the six dimensions were calculated as the mean score across coders for each session.

#### 2.6.3 | Randomization

Randomization was stratified by recruitment site. Before initiating recruitment, stratum-specific sequential identification numbers were generated and randomly preassigned in blocks of random sizes. The individual was the unit of randomization with 1:1 allocation to experimental groups. Women were randomized to the NA-II intervention or a wait-list control group. After the baseline assessment, the recruiter gave the participant a sealed envelope with the next sequential identification number from her stratum indicating to which experimental

group she had been assigned. Control group participants received usual care until after the 6-month assessment at which time they were offered the intervention.

## 2.6.4 | Statistical analysis

A power analysis conducted to establish our enrollment target of 140 women assumed 80% power, two-tailed  $\alpha$  = 0.05, and 90% retention. Intention-to-treat analyses focused on treatment  $\times$  time interaction effects at baseline, three and 6 months, for the primary outcomes of FACT-B subscale scores. The study was powered for a minimal detectable effect of the proposed design of d = 0.45as estimated by simulation.

Likelihood-based model estimation assumed outcome responses were missing at random. <sup>33</sup> Explanatory variables included an intervention group indicator, a categorical time indicator, and a treatment  $\times$  time interaction variable. Custom contrasts estimated differences between treatment groups at each assessment, as well as 2 treatment  $\times$  time interactions: one examining the change from baseline to 3 months (immediately after intervention) and one examining the change from baseline to 6 months. We compared experimental groups on primary outcomes of *breast cancer-specific quality of life* 

<sup>&</sup>lt;sup>b</sup>Depressive symptoms = PHQ-8.<sup>25</sup>

<sup>&</sup>lt;sup>c</sup>Perceived stress = Perceived Stress Scale.<sup>26</sup>

<sup>&</sup>lt;sup>d</sup>Anxiety and somatization = Brief Symptom Inventory scales.<sup>28</sup>

<sup>&</sup>lt;sup>e</sup>Stress management scales = Measure of Current Status Part A (MOCS-A).<sup>29</sup>

scales and secondary outcomes of general distress symptoms (depressive symptoms, perceived stress, anxiety, and somatization), and stress management skills(relaxation, awareness of tension, assertiveness, coping confidence).

#### 3 | RESULTS

The RCT was conducted between September 2016 and October 2018. Figure 1 shows the Consolidated Standards of Reporting Trials (CONSORT) participant flow diagram. We invited 231 women; 24 were ineligible and 54 refused. We randomly assigned the final sample of 153 women to the intervention (n = 76) or control group (n = 77) between September 2016 and March 2018. Follow-up assessments occurred from February 2017 through October 2018.

The overall sample had a mean age of 54.8 years (SD = 10.5, range 28-88) (Table 2). Eighty percent had less than a high school education, most had public insurance only (75%), the majority were unemployed (82%), and almost half (48%) reported financial hardship in the past year. Nearly all (97%) reported being Mexican and 82% had limited English proficiency. Two-thirds (66%) was married/living with a partner. Slightly less than half were in poor or fair health, and more than a third reported having poor or fair mental health.

The greatest proportion were diagnosed at stage II, with equal proportions of women receiving breast conserving vs mastectomy surgery and the majority receiving radiotherapy and chemotherapy. Average time since diagnosis was 2.5 years (SD = 3.2).

We found no significant baseline differences between intervention and control groups on demographics, clinical characteristics, quality of life, or distress outcomes, except for educational attainment and self-rated health, with the intervention group tending to be slightly better educated and more likely to report poor or fair health.

Baseline levels of breast cancer-specific quality of life were low, indicating poor quality of life (Table 2). In general, scores on *anxiety*, *somatization*, *depressive symptoms*, and *perceived stress* were low, indicating fairly low levels of general distress symptoms. Breast cancer self-management skills were fair (2.0-2.6 on a 0-4 scale). There were no significant differences between intervention and control groups at baseline on quality of life, general distress, or stress management skills.

A large percentage (86%) of the intervention group completed at least 7 of 10 weekly sessions (9% completed 1 to 6 sessions, and 5% completed no sessions). Six-month retention was 88% for the intervention group and 95% for the control group (92% overall). Mean fidelity ratings were: 4.5, extent followed manual; 4.4, used easy-to-understand language; 3.9, checked comprehension; 4.4, used caring/supportive communication; 3.8, modeled skills; and 3.9, provided feedback.




FIGURE 2 Anxiety and coping skills outcomes, Nuevo Amanecer-II study, California, September 2016 to March 2018

**TABLE 3** Quality of life, symptoms of distress, and coping skills among Spanish-speaking Latinas with breast cancer, by treatment group at baseline, 3 months, and 6 months: *Nuevo Amanecer-II* study, California, September 2016 to March 2018

|   | Intervention Mean (SD)                  | ControlMean (SD) | P-value |
|---|---|------------------|---------|
| Breast Cancer-Specific Quality of Life (higher score = better |   |                  |         |
| Physical well-being (scale 0-24)                              |   |                  |         |
| Baseline  | 17.53 (5.16)                            | 17.21 (5.51)     | 0.706   |
| 3 months  | 18.78 (4.26)                            | 18.36 (4.88)     | 0.283   |
| 6 months  | 19.12 (3.98)                            | 18.73 (4.34)     | 0.445   |
| Treatment × time interaction (0–3 months)                     |   |                  | 0.455   |
| Treatment × time interaction (0–6 months)                     |   |                  | 0.746   |
| Social/family well-being (scale 0-20)                         |   |                  |         |
| Baseline  | 13.11 (4.01)                            | 14.12 (4.10)     | 0.128   |
| 3 months  | 13.33 (3.59)                            | 13.48 (4.22)     | 0.946   |
| 6 months  | 11.76 (4.24)                            | 12.45 (4.57)     | 0.443   |
| Treatment × time interaction (0–3 months)                     |   |                  | 0.138   |
| Treatment × time interaction (0–6 months)                     |   |                  | 0.559   |
| Emotional well-being (scale 0–20)                             |   |                  |         |
| Baseline  | 14.13 (4.36)                            | 14.64 (4.30)     | 0.472   |
| 3 months  | 15.33 (3.71)                            | 15.10 (4.03)     | 0.624   |
| 6 months  | 15.30 (3.56)                            | 15.18 (4.24)     | 0.815   |
| Treatment × time interaction (0–3 months)                     | , , ,                                   | ,                | 0.158   |
| Treatment × time interaction (0–6 months)                     |   |                  | 0.298   |
| Breast cancer concerns (scale 0–28)                           |   |                  |         |
| Baseline  | 17.20 (4.69)                            | 17.50 (4.82)     | 0.692   |
| 3 months  | 17.78 (4.75)                            | 18.93 (5.31)     | 0.289   |
| 6 months  | 19.15 (4.02)                            | 19.38 (4.77)     | 0.871   |
| Treatment × time interaction (0–3 months)                     | , ,                                     | , ,              | 0.425   |
| Treatment × time interaction (0–6 months)                     |   |                  | 0.792   |
| Enjoyment of life (scale 0–16)                                |   |                  |         |
| Baseline  | 10.86 (2.81)                            | 11.10 (2.96)     | 0.608   |
| 3 months  | 10.81 (2.71)                            | 10.82 (3.01)     | 0.695   |
| 6 months  | 10.37 (3.03)                            | 10.64 (3.27)     | 0.729   |
| Treatment × time interaction (0–3 months)                     | · ·                                     | , ,              | 0.324   |
| Treatment × time interaction (0–6 months)                     |   |                  | 0.904   |
| Overall quality of life (scale 0–108)                         |   |                  |         |
| Baseline  | 72.90 (14.46)                           | 74.55 (15.71)    | 0.501   |
| 3 months  | 76.03 (13.70)                           | 76.68 (17.55)    | 0.827   |
| 6 months  | 75.70 (13.35)                           | 76.38 (17.29)    | 0.953   |
| Treatment × time interaction (0–3 months)                     | , | ,                | 0.230   |
| Treatment × time interaction (0–6 months)                     |   |                  | 0.448   |
| General Distress Symptoms (higher score = more distress)      |   |                  |         |
| Depressive symptoms (scale 0-24) <sup>b</sup>                 |   |                  |         |
| Baseline  | 6.79 (5.06)                             | 6.65 (5.48)      | 0.870   |
| 3 months  | 6.81 (5.31)                             | 6.97 (5.12)      | 0.436   |
| 6 months  | 6.96 (5.62)                             | 6.44 (5.15)      | 0.794   |
| Treatment × time interaction (0–3 months)                     | · · · · · · · · · · · · · · · · · · ·   | (2/              | 0.244   |
| Treatment × time interaction (0–6 months)                     |   |                  | 0.909   |

TABLE 3 (Continued)

| Intervention Mean (SD)  | TABLE 3 (Continued)  |                        |                  |         |
|---|--|------------------------|------------------|---------|
| Baseline         15.51 (7.63)         15.95 (7.08)         0.715           3 months         14.48 (6.63)         14.08 (7.35)         0.95 4           6 months         14.70 (6.14)         15.14 (6.28)         0.95 1           T restment x time interaction (0-6 months)         - (7.20 (7.3))         0.68 (0.80)         0.72 (2.73)           Anxiety (scale 0-4) <sup>41</sup> - (7.20 (7.3))         0.68 (0.80)         0.72 (2.73)           3 months         0.39 (0.41)         0.65 (0.70)         0.833           6 months         0.25 (0.53)         0.70 (0.64)         0.94           1 Treatment x time interaction (0-6 months)         - (7.20 (7.20))         0.049           5 months         0.47 (0.60)         0.73 (0.47)         0.58 (0.80)           3 months         0.44 (0.58)         0.72 (0.70)         0.202           4 months         0.44 (0.58)         0.72 (0.70)         0.202           6 months         0.40 (0.88)         0.72 (0.70)         0.02           7 treatment x time interaction (0-6 months)         - (0.17)         0.01           7 treatment x time interaction (0-6 months)         - (0.17)         0.02           8 months         1.78 (1.13)         2.13 (1.11)         0.03           3 months         2.60 (0.79) <th></th> <th>Intervention Mean (SD)</th> <th>ControlMean (SD)</th> <th>P-value</th>   |  | Intervention Mean (SD) | ControlMean (SD) | P-value |
| 3 months         1.4.45 (6.63)         1.4.08 (7.35)         0.975           6 months         1.4.70 (6.14)         15.14 (6.28)         0.574           1 Treatment x time interaction (0-3 months)  | Perceived stress (scale 0-40) <sup>c</sup>                           |                        |                  |         |
| 6 months         14,70 (6.14)         15.14 (6.28)         0.543           Treatment x time interaction (0-3 months)         0.885           Anxiety (scale 0-4)γ²         Seasine         0.72 (0.73)         0.68 (0.80)         0.72 (2.73)           3 months         0.63 (0.61)         0.65 (0.70)         0.833           6 months         0.52 (0.53)         0.70 (0.64)         0.094           1 months         0.52 (0.53)         0.70 (0.64)         0.094           5 months         0.52 (0.53)         0.70 (0.64)         0.094           1 months         0.52 (0.53)         0.70 (0.64)         0.094           5 months         0.65 (0.63)         0.072         0.72         0.72           3 months         0.64 (0.49)         0.72 (0.70)         0.202         0.003 <td>Baseline</td> <td>15.51 (7.63)</td> <td>15.95 (7.08)</td> <td>0.715</td>  | Baseline   | 15.51 (7.63)           | 15.95 (7.08)     | 0.715   |
| Treatment x time interaction (0-3 months)  Treatment x time interaction (0-6 months)  Anxiety (scale 0-4) <sup>41</sup> Baseline  30.72 (0.73) 30.68 (0.80) 30.72 (0.73) 30.058 (0.80) 30.72 (0.73) 30.058 (0.80) 30.72 (0.73) 30.058 (0.80) 30.70 (0.64) 30.33 (0.61) 30.52 (0.53) 30.70 (0.64) 30.904 Treatment x time interaction (0-3 months) 40.420 Treatment x time interaction (0-6 months)  Somularization (scale 0-4) <sup>41</sup> Baseline 30.64 (0.58) 30.73 (0.67) 30.93 31 months 30.64 (0.58) 30.72 (0.70) 30.93 31 months 30.64 (0.58) 30.72 (0.70) 30.93 31 months 40.64 (0.58) 40.72 (0.70) 40.93 31 months 40.72 (0.70) 40.93 31 months 40.78 (0.72) 40.64 (0.72) 40.64 (0.72) 40.64 (0.72) 40.74 (0.72) 4 | 3 months   | 14.45 (6.63)           | 14.08 (7.35)     | 0.995   |
| Treatment x time interaction (0-6 months)         0.72 (0.73)         0.48 (0.80)         0.722 (0.73)         0.48 (0.80)         0.722 (0.73)         0.68 (0.70)         0.833 (0.61)         0.65 (0.70)         0.833 (0.61)         0.65 (0.70)         0.833 (0.70)         0.69 (0.70)         0.633 (0.61)         0.05 (0.70)         0.049 (0.70)         0.049 (0.70)         0.049 (0.70)         0.049 (0.70)         0.049 (0.70)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.049 (0.72)         0.053 (0.72)         0.053 (0.72)         0.053 (0.72)         0.053 (0.72)         0.053 (0.72)         0.003 (0.72)   | 6 months   | 14.70 (6.14)           | 15.14 (6.28)     | 0.574   |
| Baseline  | Treatment × time interaction (0–3 months)                            |                        |                  | 0.633   |
| Baseline         0.72 (0.73)         0.68 (0.80)         0.72 (0.73)           3 months         0.63 (0.61)         0.65 (0.70)         0.83 (0.73)           6 months         0.52 (0.53)         0.70 (0.64)         0.694 (0.69)           Treatment x time interaction (0-6 months)   | Treatment × time interaction (0–6 months)                            |                        |                  | 0.885   |
| 3 months 0.63 (0.61) 0.65 (0.70) 0.83 (0.70 (0.64) 0.094 (0.70 (0.70 (0.64) 0.094 (0.70                      | Anxiety (scale 0–4) <sup>d</sup>                                     |                        |                  |         |
| 6 months 0.52 (0.53) 0.70 (0.64) 0.99  Treatment x time interaction (0-3 months) 0.492  Treatment x time interaction (0-6 months) 0.699  Somatization (scale 0-4)9  Baseline 0.67 (0.60) 0.73 (0.67) 0.538  3 months 0.64 (0.88) 0.72 (0.70) 0.202  6 months 0.648 (0.48) 0.65 (0.63) 0.032  7 treatment x time interaction (0-3 months) 0.48 (0.45) 0.65 (0.63) 0.032  Treatment x time interaction (0-6 months) 0.48 (0.45) 0.65 (0.63) 0.032  Treatment x time interaction (0-6 months) 0.48 (0.45) 0.55 (0.63) 0.032  Treatment x time interaction (0-6 months) 0.78 (0.72) 0.117  Stress Management Skills (higher score ≈ better skills)*  Relaxation skills (scale 0-4)  Baseline 1.78 (1.13) 2.13 (1.11) 0.053  3 months 2.76 (0.72) 2.04 (0.94) 0.004  4 months 2.60 (0.79) 2.17 (0.94) 0.004  Treatment x time interaction (0-3 months) 2.60 (0.79) 2.17 (0.94) 0.004  Treatment x time interaction (0-3 months) 2.63 (0.63) 0.230 (0.77) 0.003  3 months 2.63 (0.64) 2.30 (0.77) 0.003  6 months 2.63 (0.64) 2.30 (0.77) 0.004  Treatment x time interaction (0-3 months) 2.61 (0.64) 2.30 (0.76) 0.049  Treatment x time interaction (0-3 months) 2.61 (0.64) 2.30 (0.76) 0.049  Treatment x time interaction (0-6 months) 2.59 (1.11) 2.49 (1.22) 0.579  3 months 2.64 (0.91) 2.33 (0.88) 0.015  6 months 2.59 (0.11) 2.49 (0.96) 0.601  Treatment x time interaction (0-3 months) 2.59 (1.11) 2.49 (0.96) 0.601  Treatment x time interaction (0-3 months) 2.59 (0.11) 2.49 (0.96) 0.601  Treatment x time interaction (0-6 months) 2.59 (0.11) 2.49 (0.96) 0.601  Treatment x time interaction (0-6 months) 2.59 (0.91) 2.30 (0.70) 0.003  Treatment x time interaction (0-6 months) 2.59 (0.91) 2.30 (0.70) 0.004  Treatment x time interaction (0-6 months) 2.59 (0.91) 2.30 (0.70) 0.004  Treatment x time interaction (0-6 months) 2.59 (0.91) 2.30 (0.70) 0.004  Treatment x time interaction (0-6 months) 2.59 (0.91) 2.30 (0.70) 0.004  Treatment x time interaction (0-6 months) 2.50 (0.80) 0.004  Treatment x time interaction (0-6 months) 2.50 (0.80) 0.004  Treatment x time interaction (0-6 mon                     | Baseline   | 0.72 (0.73)            | 0.68 (0.80)      | 0.722   |
| Treatment x time interaction (0-3 months)         0.494           Treatment x time interaction (0-6 months)         0.049           Somatization (scale 0-4)*         0.67 (0.60)         0.73 (0.67)         0.53 (0.83)           3 months         0.64 (0.58)         0.72 (0.70)         0.202           6 months         0.48 (0.45)         0.65 (0.63)         0.03           Treatment x time interaction (0-3 months)         1.70         0.70         0.70           Treatment x time interaction (0-6 months)         0.48 (0.45)         0.65 (0.63)         0.03           Treatment x time interaction (0-6 months)         0.01         0.01         0.00         0.0  | 3 months   | 0.63 (0.61)            | 0.65 (0.70)      | 0.833   |
| Treatment x time interaction (0-6 months)         0.047 (0.60)         0.73 (0.67)         0.538           Baseline         0.64 (0.58)         0.72 (0.70)         0.202           3 months         0.48 (0.45)         0.65 (0.63)         0.032           6 months         0.48 (0.45)         0.65 (0.63)         0.032           7 reatment x time interaction (0-3 months)         1.78 (1.13)         0.13 (1.11)         0.053           8 ascline         1.78 (1.13)         2.13 (1.11)         0.053           3 months         2.76 (0.72)         2.06 (0.96)         -0001           6 months         2.76 (0.72)         2.06 (0.96)         -0001           6 months         2.50 (0.79)         2.17 (0.94)         0.004           7 reatment x time interaction (0-3 months)         2.50 (0.79)         2.17 (0.94)         0.001           6 months         2.32 (0.88)         2.49 (1.05)         0.28           3 months         2.53 (0.61)         2.30 (0.77)         0.003           6 months         2.61 (0.66)         2.38 (0.76)         0.004           7 reatment x time interaction (0-3 months)         2.59 (1.11)         2.49 (1.22)         0.579           3 months         2.64 (0.91)         2.33 (0.88)         0.01 <t< td=""><td>6 months</td><td>0.52 (0.53)</td><td>0.70 (0.64)</td><td>0.094</td></t<>  | 6 months   | 0.52 (0.53)            | 0.70 (0.64)      | 0.094   |
| Somatization (scale 0-4) <sup>d</sup>   | Treatment × time interaction (0–3 months)                            |                        |                  | 0.492   |
| Baseline         0.67 (0.60)         0.73 (0.67)         0.53           3 months         0.64 (0.58)         0.72 (0.70)         0.202           6 months         0.48 (0.45)         0.65 (0.63)         0.032           Treatment x time interaction (0-3 months)   | Treatment × time interaction (0–6 months)                            |                        |                  | 0.049   |
| 3 months 0.64 (0.58) 0.72 (0.70) 0.202 6 months 0.48 (0.45) 0.65 (0.63) 0.032 1 Treatment x time interaction (0-3 months) 0.380 0.380 0.330 0.3                     | Somatization (scale 0-4) <sup>d</sup>                                |                        |                  |         |
| 6 months         0.48 (0.45)         0.65 (0.63)         0.038 (0.48)           Treatment × time interaction (0~6 months)         0.380 (0.17)           Streatment × time interaction (0~6 months)         0.117           Streast Management Skills (higher score = better skills)*           Relaxation skills (scale 0~4)           Baseline         1.78 (1.13)         2.13 (1.11)         0.053           3 months         2.76 (0.72)         2.06 (0.96)         <.0001  | Baseline   | 0.67 (0.60)            | 0.73 (0.67)      | 0.538   |
| Treatment × time interaction (0-3 months)         0.380           Treatment × time interaction (0-6 months)         0.117           Stress Management Skills (higher score = better skills)**           Relaxation skills (scale 0-4)           Baseline         1.78 (1.13)         2.13 (1.11)         0.053           3 months         2.76 (0.72)         2.06 (0.96)         <0001   | 3 months   | 0.64 (0.58)            | 0.72 (0.70)      | 0.202   |
| Treatment × time interaction (0-6 months)         0.117           Stress Management Skills (higher score = better skills)**           Relaxation skills (scale 0-4)           Baseline         1.78 (1.13)         2.13 (1.11)         0.053           3 months         2.76 (0.72)         2.06 (0.96)         <0.001  | 6 months   | 0.48 (0.45)            | 0.65 (0.63)      | 0.032   |
| Stress Management Skills (higher score = better skills)*           Relaxation skills (scale 0-4)  | Treatment × time interaction (0–3 months)                            |                        |                  | 0.380   |
| Relaxation skills (scale 0-4)         1.78 (1.13)         2.13 (1.11)         0.053           3 months         2.76 (0.72)         2.06 (0.96)         <.0001   | Treatment × time interaction (0–6 months)                            |                        |                  | 0.117   |
| Baseline         1.78 (1.13)         2.13 (1.11)         0.053           3 months         2.76 (0.72)         2.06 (0.96)         <.0001  | Stress Management Skills (higher score = better skills) <sup>e</sup> |                        |                  |         |
| 3 months       2.76 (0.72)       2.06 (0.96)       <.001  | Relaxation skills (scale 0-4)  |                        |                  |         |
| 6 months 2.60 (0.79) 2.17 (0.94) 0.004 Treatment x time interaction (0-3 months) Treatment x time interaction (0-6 months)  Awareness of tension (scale 0-4)  Baseline 2.32 (0.88) 2.49 (1.05) 0.283 3 months 2.63 (0.61) 2.30 (0.77) 0.003 6 months 2.61 (0.66) 2.38 (0.76) 0.049 Treatment x time interaction (0-3 months) 0.002 Treatment x time interaction (0-6 months) 2.59 (1.11) 2.49 (1.22) 0.579 3 months 2.59 (1.11) 2.49 (1.22) 0.579 3 months 2.64 (0.91) 2.33 (0.88) 0.015 6 months 2.55 (0.91) 2.49 (0.96) 0.601 Treatment x time interaction (0-6 months) 2.55 (0.91) 2.49 (0.96) 0.601 Treatment x time interaction (0-6 months) 2.55 (0.91) 2.49 (0.96) 0.601 Treatment x time interaction (0-6 months) 2.55 (0.91) 2.49 (0.96) 0.601 Treatment x time interaction (0-6 months) 2.55 (0.91) 2.53 (1.01) 0.607 3 months 2.55 (0.80) 2.53 (1.01) 0.607 3 months 2.57 (0.66) 2.30 (0.70) 0.016 6 months 2.59 (0.75) 2.46 (0.72) 0.676 Treatment x time interaction (0-3 months) 2.50 (0.75) 2.46 (0.72) 0.676  | Baseline   | 1.78 (1.13)            | 2.13 (1.11)      | 0.053   |
| Treatment x time interaction (0-3 months)         <.0001  | 3 months   | 2.76 (0.72)            | 2.06 (0.96)      | <.0001  |
| Treatment x time interaction (0-6 months)         0,0001           Awareness of tension (scale 0-4)         2,32 (0.88)         2.49 (1.05)         0,283           3 months         2.63 (0.61)         2,30 (0.77)         0,003           6 months         2.61 (0.66)         2,38 (0.76)         0,049           Treatment x time interaction (0-3 months)         7         0,002         0,002           Treatment x time interaction (0-6 months)         2.59 (1.11)         2.49 (1.22)         0,579           3 months         2.64 (0.91)         2.33 (0.88)         0,015           6 months         2.55 (0.91)         2.49 (0.96)         0,601           Treatment x time interaction (0-3 months)         2.55 (0.91)         2.49 (0.96)         0,601           Treatment x time interaction (0-6 months)         2.50 (0.91)         2.53 (1.01)         0,607           Baseline         2.45 (0.80)         2.53 (1.01)         0,607           3 months         2.57 (0.66)         2.30 (0.70)         0,016           6 months         2.50 (0.75)         2.46 (0.72)         0,676           Treatment x time interaction (0-3 months)         2.50 (0.75)         2.46 (0.72)         0,676  | 6 months   | 2.60 (0.79)            | 2.17 (0.94)      | 0.004   |
| Awareness of tension (scale 0-4)       2.32 (0.88)       2.49 (1.05)       0.283         3 months       2.63 (0.61)       2.30 (0.77)       0.003         6 months       2.61 (0.66)       2.38 (0.76)       0.049         Treatment x time interaction (0-3 months)       0.002       0.002         Treatment x time interaction (0-6 months)       0.015       0.015         Assertiveness (scale 0-4)       2.59 (1.11)       2.49 (1.22)       0.579         3 months       2.64 (0.91)       2.33 (0.88)       0.015         6 months       2.55 (0.91)       2.49 (0.96)       0.601         Treatment x time interaction (0-3 months)       0.113       0.113         Treatment x time interaction (0-6 months)       0.895         Coping confidence (scale 0-4)       2.50 (0.75)       2.53 (1.01)       0.607         3 months       2.57 (0.66)       2.30 (0.70)       0.016         6 months       2.50 (0.75)       2.46 (0.72)       0.676         Treatment x time interaction (0-3 months)       0.008       0.008  | Treatment × time interaction (0–3 months)                            |                        |                  | <.0001  |
| Baseline       2.32 (0.88)       2.49 (1.05)       0.283         3 months       2.63 (0.61)       2.30 (0.77)       0.003         6 months       2.61 (0.66)       2.38 (0.76)       0.049         Treatment × time interaction (0-3 months)       0.002       0.002         Treatment × time interaction (0-6 months)  | Treatment × time interaction (0–6 months)                            |                        |                  | 0.0001  |
| 3 months       2.63 (0.61)       2.30 (0.77)       0.003         6 months       2.61 (0.66)       2.38 (0.76)       0.049         Treatment x time interaction (0-3 months)       0.002       0.002         Treatment x time interaction (0-6 months)       0.015         Assertiveness (scale 0-4)       0.579         3 months       2.64 (0.91)       2.33 (0.88)       0.015         6 months       2.55 (0.91)       2.49 (0.96)       0.601         Treatment x time interaction (0-3 months)       0.895         Coping confidence (scale 0-4)       0.607       0.895         Baseline       2.45 (0.80)       2.53 (1.01)       0.607         3 months       2.57 (0.66)       2.30 (0.70)       0.016         6 months       2.50 (0.75)       2.46 (0.72)       0.676         Treatment x time interaction (0-3 months)       0.008       0.008  | Awareness of tension (scale 0-4)                                     |                        |                  |         |
| 6 months 2.61 (0.66) 2.38 (0.76) 0.049  Treatment × time interaction (0-3 months) 0.002  Treatment × time interaction (0-6 months) 0.015  Assertiveness (scale 0-4)  Baseline 2.59 (1.11) 2.49 (1.22) 0.579  3 months 2.64 (0.91) 2.33 (0.88) 0.015  6 months 2.55 (0.91) 2.49 (0.96) 0.601  Treatment × time interaction (0-3 months) 0.113  Treatment × time interaction (0-6 months) 0.895  Coping confidence (scale 0-4)  Baseline 2.45 (0.80) 2.53 (1.01) 0.607  3 months 2.57 (0.66) 2.30 (0.70) 0.016  6 months 2.50 (0.75) 2.46 (0.72) 0.676  Treatment × time interaction (0-3 months) 0.008   | Baseline   | 2.32 (0.88)            | 2.49 (1.05)      | 0.283   |
| Treatment × time interaction (0-3 months)       0.002         Treatment × time interaction (0-6 months)       0.015         Assertiveness (scale 0-4)       2.59 (1.11)       2.49 (1.22)       0.579         3 months       2.64 (0.91)       2.33 (0.88)       0.015         6 months       2.55 (0.91)       2.49 (0.96)       0.601         Treatment × time interaction (0-3 months)       0.113       0.113         Treatment × time interaction (0-6 months)       0.895         Coping confidence (scale 0-4)       2.45 (0.80)       2.53 (1.01)       0.607         3 months       2.57 (0.66)       2.30 (0.70)       0.016         6 months       2.50 (0.75)       2.46 (0.72)       0.676         Treatment × time interaction (0-3 months)       0.008       0.008       0.008   | 3 months   | 2.63 (0.61)            | 2.30 (0.77)      | 0.003   |
| Treatment × time interaction (0-6 months)       0.015         Assertiveness (scale 0-4)       2.59 (1.11)       2.49 (1.22)       0.579         3 months       2.64 (0.91)       2.33 (0.88)       0.015         6 months       2.55 (0.91)       2.49 (0.96)       0.601         Treatment × time interaction (0-3 months)       0.113       0.895         Coping confidence (scale 0-4)         Baseline       2.45 (0.80)       2.53 (1.01)       0.607         3 months       2.57 (0.66)       2.30 (0.70)       0.016         6 months       2.50 (0.75)       2.46 (0.72)       0.676         Treatment × time interaction (0-3 months)       0.008  | 6 months   | 2.61 (0.66)            | 2.38 (0.76)      | 0.049   |
| Assertiveness (scale 0-4)       2.59 (1.11)       2.49 (1.22)       0.579         3 months       2.64 (0.91)       2.33 (0.88)       0.015         6 months       2.55 (0.91)       2.49 (0.96)       0.601         Treatment × time interaction (0-3 months)       0.113       0.895         Treatment × time interaction (0-6 months)       0.895       0.607         Baseline       2.45 (0.80)       2.53 (1.01)       0.607         3 months       2.57 (0.66)       2.30 (0.70)       0.016         6 months       2.50 (0.75)       2.46 (0.72)       0.676         Treatment × time interaction (0-3 months)       0.008  | Treatment × time interaction (0–3 months)                            |                        |                  | 0.002   |
| Baseline       2.59 (1.11)       2.49 (1.22)       0.579         3 months       2.64 (0.91)       2.33 (0.88)       0.015         6 months       2.55 (0.91)       2.49 (0.96)       0.601         Treatment × time interaction (0-3 months)       0.113       0.113         Treatment × time interaction (0-6 months)       0.895       0.895         Coping confidence (scale 0-4)       2.53 (1.01)       0.607         3 months       2.57 (0.66)       2.30 (0.70)       0.016         6 months       2.50 (0.75)       2.46 (0.72)       0.676         Treatment × time interaction (0-3 months)       0.008  | Treatment × time interaction (0–6 months)                            |                        |                  | 0.015   |
| 3 months 2.64 (0.91) 2.33 (0.88) 0.015 6 months 2.55 (0.91) 2.49 (0.96) 0.601 Treatment × time interaction (0-3 months) 0.113 Treatment × time interaction (0-6 months) 0.895  Coping confidence (scale 0-4)  Baseline 2.45 (0.80) 2.53 (1.01) 0.607 3 months 2.57 (0.66) 2.30 (0.70) 0.016 6 months 2.50 (0.75) 2.46 (0.72) 0.676 Treatment × time interaction (0-3 months) 0.008  | Assertiveness (scale 0-4)  |                        |                  |         |
| 6 months 2.55 (0.91) 2.49 (0.96) 0.601  Treatment × time interaction (0-3 months) 0.113  Treatment × time interaction (0-6 months) 0.895  Coping confidence (scale 0-4)  Baseline 2.45 (0.80) 2.53 (1.01) 0.607  3 months 2.57 (0.66) 2.30 (0.70) 0.016  6 months 2.50 (0.75) 2.46 (0.72) 0.676  Treatment × time interaction (0-3 months) 0.008  | Baseline   | 2.59 (1.11)            | 2.49 (1.22)      | 0.579   |
| Treatment × time interaction (0-3 months)       0.113         Treatment × time interaction (0-6 months)       0.895         Coping confidence (scale 0-4)       2.45 (0.80)       2.53 (1.01)       0.607         3 months       2.57 (0.66)       2.30 (0.70)       0.016         6 months       2.50 (0.75)       2.46 (0.72)       0.676         Treatment × time interaction (0-3 months)       0.008   | 3 months   | 2.64 (0.91)            | 2.33 (0.88)      | 0.015   |
| Treatment × time interaction (0-6 months)       0.895         Coping confidence (scale 0-4)         Baseline       2.45 (0.80)       2.53 (1.01)       0.607         3 months       2.57 (0.66)       2.30 (0.70)       0.016         6 months       2.50 (0.75)       2.46 (0.72)       0.676         Treatment × time interaction (0-3 months)       0.008  | 6 months   | 2.55 (0.91)            | 2.49 (0.96)      | 0.601   |
| Coping confidence (scale 0-4)         Baseline       2.45 (0.80)       2.53 (1.01)       0.607         3 months       2.57 (0.66)       2.30 (0.70)       0.016         6 months       2.50 (0.75)       2.46 (0.72)       0.676         Treatment × time interaction (0-3 months)       0.008  | Treatment × time interaction (0–3 months)                            |                        |                  | 0.113   |
| Baseline       2.45 (0.80)       2.53 (1.01)       0.607         3 months       2.57 (0.66)       2.30 (0.70)       0.016         6 months       2.50 (0.75)       2.46 (0.72)       0.676         Treatment × time interaction (0-3 months)       0.008  | Treatment × time interaction (0–6 months)                            |                        |                  | 0.895   |
| 3 months       2.57 (0.66)       2.30 (0.70)       0.016         6 months       2.50 (0.75)       2.46 (0.72)       0.676         Treatment × time interaction (0-3 months)       0.008   | Coping confidence (scale 0-4)  |                        |                  |         |
| 6 months 2.50 (0.75) 2.46 (0.72) 0.676  Treatment × time interaction (0-3 months) 0.008   | Baseline   | 2.45 (0.80)            | 2.53 (1.01)      | 0.607   |
| 6 months 2.50 (0.75) 2.46 (0.72) 0.676  Treatment × time interaction (0-3 months) 0.008   | 3 months   | 2.57 (0.66)            | 2.30 (0.70)      | 0.016   |
| Treatment × time interaction (0–3 months) 0.008   | 6 months   |                        |                  | 0.676   |
|   | Treatment × time interaction (0–3 months)                            |                        |                  | 0.008   |
|   | Treatment × time interaction (0–6 months)                            |                        |                  | 0.345   |

<sup>&</sup>lt;sup>a</sup>Breast cancer-specific quality of life scales = FACT-B scales.<sup>23</sup>

<sup>&</sup>lt;sup>b</sup>Depressive symptoms = PHQ-8.<sup>25</sup>

<sup>&</sup>lt;sup>c</sup>Perceived stress = Perceived Stress Scale.<sup>26</sup>

<sup>&</sup>lt;sup>d</sup>Anxiety and somatization = Brief Symptom Inventory scales.<sup>28</sup>

<sup>&</sup>lt;sup>e</sup>Stress management scales = Measure of Current Status Part A (MOCS-A).<sup>29</sup>

Primary outcomes: breast cancer-specific quality of life. There were no statistically significant treatment  $\times$  time interaction effects on quality of life outcomes at 3 or 6 months (Table 3).

Secondary outcomes: general distress symptoms. From baseline to 6 months (3 months post-intervention), we found significant treatment  $\times$  time interaction effects on anxiety (P = .049), with the intervention group reporting greater improvement than the control group (-0.20 vs -0.02; range 0-4) (Figure 2). At 6 months, scores on somatization in the intervention group were significantly lower than in the control group (0.48 vs 0.65; range 0-4; P < 0.05). However, there were no significant treatment  $\times$  time interaction effects for somatization. There were no significant treatment  $\times$  time effects on depressive symptoms or perceived stress.

Secondary outcomes: stress management skills (range 0-4). The effects of the intervention on stress management skills varied. For relaxation, we observed significant treatment  $\times$  time interaction effects at 3 months (P < 0.0001) and 6 months (P < 0.001). At 3 months, women in the intervention group experienced greater improvement in their relaxation skills than women from the control group (+0.98 vs -0.07). Positive effects on relaxation skills in the intervention group were maintained (+0.82) at 6 months (Figure 2).

For awareness of tension, we observed significant treatment  $\times$  time interaction effects at 3 months (P < 0.01) and 6 months (P < 0.05). At 3 months, intervention group women experienced greater improvement in awareness of tension than the control group (+0.31 vs -0.19). Effects on awareness of tension in the intervention group were maintained (+0.29) at 6 months (Figure 2).

For assertiveness, we did not observe any treatment  $\times$  time interaction effects, but 3-month scores were significantly higher for the intervention (2.64) than control group (2.33) (P < 0.05).

For *coping confidence*, we observed significant treatment  $\times$  time interaction effects at 3 months (P < 0.01). The intervention group improved their *coping confidence* from 2.45 to 2.57 (+0.12) at 3 months while the control group's scores declined from 2.53 to 2.30 (-0.23) (Figure 2).

## 4 | DISCUSSION

In this study, we continued translation of our cognitive-behavioral stress management program to be suitable for rural and urban Spanish-speaking Latina breast cancer survivors through long-term survivorship. We were able to reach and retain vulnerable, rural-dwelling survivors. Compared to a wait-list control group, women who received the intervention reported significant reductions in anxiety and improvements in several stress management skills, including their ability to relax at will, be aware of tension, and their confidence in coping with problems. However, there were no significant effects of the intervention on breast cancer-specific quality of life.

The lack of effects on quality of life in this trial are inconsistent with our prior RCT among urban Latina breast cancer survivors. In that study, several quality of life domains improved including physical and emotional well-being, breast cancer concerns, and overall quality

of life, with no significant effects on anxiety. But in that study, all women were enrolled within 1 year of diagnosis and most within 3 months, whereas women in this trial were farther from diagnosis (within 2.5 years on average). Quality of life measures were breast cancer-specific and may not have been as relevant in this study as more general measures of quality of life and distress. Also, possibly due to their longer time since diagnosis, baseline levels of quality of life among women in this study were better than those in our prior RCT, leaving less room for improvement. Our positive results with respect to anxiety in this trial are consistent with one other single-arm trial in a small group of Latinas that found significant improvements in anxiety with an 8-week mindfulness stress reduction program<sup>14</sup>.

Women in this study had several vulnerabilities including rural residence, low socioeconomic status, financial hardship, dependency on public insurance, high level of unemployment and disability, limited English proficiency, and immigrant status. For breast cancer survivors facing these vulnerabilities, providing a sense of confidence in their ability to cope with problems and reduce anxiety may be especially helpful. Since we did not see significant improvements in a general stress measure among the intervention group compared to the control group, it is possible that a more intensive or longer stress management program or a different type of program may be needed to effectively reduce stress in this especially vulnerable group. At a minimum, community partners increased their capacity to deliver evidence-based stress management skills training.

#### 4.1 | Study limitations

Study limitations include that the sample consisted of Latina breast cancer survivors of Mexican origin only, living in rural California communities. However, many of the cultural values incorporated into the intervention, for example, familismo, spirituality, fatalism and respect are shared by Latinos broadly and cut across national origin. Careful attention was paid in the formative work for this and the prior RCT to ensure that the program met the needs of both rural and urban Latinas. Therefore, it is likely that the program would generalize to Latinas from other national origin groups in the U.S.

## 4.2 | Clinical implications

Among breast cancer survivors, stress has been linked to immunological suppression and cancer progression, thus, reducing stress has important implications for preventing recurrence.<sup>34</sup> There are significant disparities in self-reported stress by socioeconomic status and race, and these stressors are known to have downstream effects on a range of psychological, neurobiological, and physiological processes and health behaviors.<sup>35</sup> Providing vulnerable populations with the skills to reduce chronic stress in their lives could provide broader advantages to their health and well-being given the cascade of illeffects and suffering that such stress can inflict.

# 5 | CONCLUSIONS

A 2017 report by the National Academies of Sciences, Engineering, and Medicine provides a strong rationale for the community as the locus for confronting health inequities. They argue persuasively that solutions for health disparities involve local community action with a range of partners.<sup>36</sup> Contributing to community infrastructure to address root causes of social and economic inequities and accompanying stress is a promising pathway to health equity,<sup>36</sup> particularly for vulnerable cancer survivors.

#### **ACKNOWLEDGEMENTS**

This research was supported by funds from the California Breast Cancer Research Grants Program Office of the University of California, grant number 21OB-0135, the Division of Intramural Research of the National Institute on Minority Health and Health Disparities, and grant number P30 AG15272 from the National Institute on Aging. We are grateful for the support and commitment of the community partners and their staff and the referring agencies and health care providers. We are indebted to the staff and Latinas living with breast cancer who made this study possible.

#### **CONFLICT OF INTEREST**

The authors declare no conflicts of interest.

#### **DISCLAIMER**

The contents and views in this manuscript are those of the authors and should not be construed to represent the views of the National Institutes of Health.

## **DATA AVAILABILITY STATEMENT**

In accordance with the NIH Data Sharing Policy, de-identified data collected as a part of this study and supporting documentation will be made available to other researchers who contact the Principal Investigator directly and complete a data transfer agreement.

#### ORCID

Anna María Nápoles https://orcid.org/0000-0001-8838-2899

#### **REFERENCES**

- Weaver KE, Geiger AM, Lu L, Case LD. Rural-urban disparities in health status among US cancer survivors. Cancer. 2013;119(5):1050-1057.
- 2. Charlton M, Schlichting J, Chioreso C, Ward M, Vikas P. Challenges of rural cancer care in the United States. *Oncologia*. 2015;29(9):633-640.
- Angell KL, Kreshka MA, McCoy R, et al. Psychosocial intervention for rural women with breast cancer: the sierra-Stanford partnership. J Gen Intern Med. 2003;18(7):499-507.
- Mollica MA, Weaver KE, McNeel TS, Kent EE. Examining urban and rural differences in perceived timeliness of care among cancer patients: a SEER-CAHPS study. Cancer. 2018;124(15):3257-3265.
- Ko E, Zuniga ML, Palomino H, Peacher D, Watson M. Qualitative study of Latino cancer patient perspectives on care access and continuity in a rural, U.S.-Mexico border region. J Immigr Minor Health. 2018;20(3):674-679.

- Ko E, Zuniga ML, Peacher D, Palomino H, Watson M. Efficacy of cancer care communication between clinicians and Latino patients in a rural US-Mexico border region: a qualitative study of barriers and facilitators to better communication. J Cancer Educ. 2018;33(1): 116-127
- Tang M, Liu X, Wu Q, Shi Y.The effects of cognitive-behavioral stress management for breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. *Cancer Nurs*. 2020; 43(3):222-237. [Epub ahead of print]. https://doi.org/10.1097/NCC
- Stagl JM, Lechner SC, Carver CS, et al. A randomized controlled trial of cognitive-behavioral stress management in breast cancer: survival and recurrence at 11-year follow-up. *Breast Cancer Res Treat*. 2015; 154(2):319-328.
- Witek-Janusek L, Albuquerque K, Chroniak KR, Chroniak C, Durazo-Arvizu R, Mathews HL. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. *Brain Behav Immun*. 2008;22(6): 969-981.
- Ashing K, Rosales M. A telephonic-based trial to reduce depressive symptoms among Latina breast cancer survivors. *Psychooncology*. 2014:23(5):507-515.
- Yanez B, Thompson EH, Stanton AL. Quality of life among Latina breast cancer patients: a systematic review of the literature. J Cancer Surviv. 2011;5(2):191-207.
- Apollo AJ, Crew KD, Campbell J, Greenlee H, Jacobson JS, Grann V, et al. High rates of psychosocial stress among Hispanic breast cancer survivors. J Clin Oncol. 2012;31(5):548-551. https://doi.org/10.1037/ a0026834
- Rush CL, Darling M, Elliott MG, et al. Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res. 2015;24(5):1107-1118.
- Elimimian E, Elson L, Bilani N, et al. Long-term effect of a nonrandomized psychosocial mindfulness-based intervention in Hispanic/Latina breast cancer survivors. *Integr Cancer Ther.* 2020;19: 1534735419890682.
- Dwight-Johnson M, Ell K, Lee PJ. Can collaborative care address the needs of low-income Latinas with comorbid depression and cancer? Results from a randomized pilot study. *Psychosomatics*. 2005;46(3): 224-232.
- Badger TA, Segrin C, Sikorskii A, et al. Randomized controlled trial of supportive care interventions to manage psychological distress and symptoms in Latinas with breast cancer and their informal caregivers. *Psychol Health*. 2020;35(1):87-106.
- Zhou ES, Partridge AH, Blackmon JE, Morgan E, Recklitis CJ. A pilot videoconference group stress management program in cancer survivors: lessons learned. Rural Remote Health. 2016;16(2):3863.
- Napoles AM, Ortiz C, Santoyo-Olsson J, et al. Nuevo Amanecer: results of a randomized controlled trial of a community-based, peer-delivered stress management intervention to improve quality of life in Latinas with breast cancer. Am J Public Health. 2015;105(Suppl 3):e55-e63.
- Santoyo-Olsson J, Stewart AL, Samayoa C, et al. Translating a stress management intervention for rural Latina breast cancer survivors: the Nuevo Amanecer-II. PLoS ONE. 2019;14(10):e0224068.
- Napoles AM, Stewart AL. Transcreation: an implementation science framework for community-engaged behavioral interventions to reduce health disparities. BMC Health Serv Res. 2018;18(1):710.
- Bandura A. Self-Efficacy: the Exercise of Control. New York, NY: Freeman: Worth Publishers; 1997.
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-381.

- 23. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. *J Clin Oncol.* 1997;15(3):974-986.
- Cella D, Hernandez L, Bonomi AE, et al. Spanish language translation and initial validation of the functional assessment of cancer therapy quality-of-life instrument. *Med Care*. 1998;36(9):1407-1418.
- Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH.
   The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1–3):163-173.
- Cohen S. 1988. Perceived stress in a probability sample of the United States. In: Sparapan S, & Oskamp S, (Eds.). The Claremont Symposium on Applied Social Psychology. The social psychology of health (p. 31-67). Newbury Park, CA: Sage Publications, Inc.
- Perera MJ, Brintz CE, Birnbaum-Weitzman O, et al. Factor structure of the perceived stress Scale-10 (PSS) across English and Spanish language responders in the HCHS/SOL sociocultural ancillary study. Psychol Assess. 2017;29(3):320-328.
- 28. Derogatis LR. The psychosocial adjustment to illness scale (PAIS). *J Psychosom Res.* 1986;30(1):77-91.
- Antoni MH, Lechner SC, Kazi A, et al. How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol. 2006;74(6):1143-1152.
- Penedo FJ, Traeger L, Dahn J, et al. Cognitive behavioral stress management intervention improves quality of life in Spanish monolingual hispanic men treated for localized prostate cancer: results of a randomized controlled trial. *Int J Behav Med.* 2007;14(3):164-172.
- Penedo FJ, Dahn JR, Molton I, et al. Cognitive-behavioral stress management improves stress-management skills and quality of life in men

- recovering from treatment of prostate carcinoma. *Cancer.* 2004;100 (1):192-200.
- Marin G, Sabogal F, Marin BV, Otero-Sabogal R, Perez-Stable EJ. Development of a short acculturation scale for Hispanics. *Hispanic J Beh Sci.* 1987;9(9):183-205.
- Little R, Rubin D. Statistical Analysis with Missing Data. 2nd ed. New York, NY: Wiley; 2002. https://doi.org/10.1002/9781119013563
- Antoni MH, Lutgendorf SK, Cole SW, et al. The influence of biobehavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer. 2006;6(3):240-248.
- American Psychological Association. APA Working Group on Stress and Health Disparities. (2017). Stress and health disparities: Contexts, mechanisms, and interventions among racial/ethnic minority and lowsocioeconomic status populations. Retrieved from http://www.apa. org/pi/health-disparities/resources/stress-report.aspx
- National Academies of Sciences, Engineering, and Medicine. Communities in Action: Pathways to Health Equity. Washington, D.C: National Academies Press; 2017. https://doi.org/10.17226/24624

How to cite this article: Nápoles AM, Santoyo-Olsson J, Stewart AL, et al. *Nuevo Amanecer-II*: Results of a randomized controlled trial of a community-based participatory, peerdelivered stress management intervention for rural Latina breast cancer survivors. *Psycho-Oncology*. 2020;29: 1802–1814. https://doi.org/10.1002/pon.5481